Cancer peptide vaccines represent one of the strategies used to control cancers by inducing robust MHC class I-restricted peptide-specific CD8+ T cells with long-lasting responses to overcome the tumor-immunosuppressive environment. This evidence concerns the gene CD8A and cancer.